ClinicalTrials.gg
RecruitingNCT07357571Updated Jan 22, 2026

Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound

An observational study in Thyroid Papillary Carcinoma and Contrast Enhanced Ultrasound, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.

Planned enrollment
8th of 19
600 · median 541
Started
2025
with 4 others
Observational
19 of 40
15 open now
Primary completion
2026-12
later than 14 of 24 live
Registered
38th of 40
by date
Lead sponsor
6 of 40
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 8th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2025, is one of 19 observational ones, reaches primary completion later than 14 of the 24 other live ones, and was the 38th registered.

Thyroid Cancer, Papillary

187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.

Browse Thyroid Cancer, Papillary studies →

Open to participants now

24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Thyroid Cancer, Papillary with a site in China, or all of them as a file.
02

Study summary

Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden lymph node metastasis is suitable for lobectomy; and high-burden lymph node metastasis recommends total thyroidectomy. However, conventional preoperative imaging examinations have low efficacy in diagnosing central lymph node metastasis. This multicenter retrospective cross-sectional study enrolled 600 patients with T1N0M0 PTC who were admitted to our hospital from June 2018 to June 2025 and confirmed by postoperative pathology. Dynamic contrast-enhanced ultrasound (CEUS) images of the thyroid and lymph nodes before surgery were collected for all patients. Two senior ultrasound physicians unaware of the pathological results independently analyzed the images and extracted qualitative and quantitative CEUS features of lesions and suspicious lymph nodes. Taking postoperative pathological results as the gold standard, patients were divided into the high-burden metastasis group, low-burden metastasis group, and non-metastasis group. Univariate and multivariate Logistic regression analyses were used to screen independent predictors, construct a combined predictive model, and draw receiver operating characteristic (ROC) curves and decision curves to evaluate its diagnostic efficacy and clinical practicality. The primary outcome measure was the area under the curve (AUC), and the secondary outcome measures included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and net benefit. This project is expected to achieve accurate preoperative prediction of the burden of central lymph node metastasis and realize precise and individualized treatment for patients with T1N0M0 PTC.

Read the detailed description

Papillary thyroid carcinoma (PTC) is the most prevalent subtype of thyroid malignancy, accounting for approximately 80%-90% of all thyroid cancers globally. With the widespread application of high-resolution ultrasound in routine physical examinations, an increasing number of early-stage PTC cases, particularly those classified as T1N0M0 (tumor size ≤2 cm, no clinical evidence of lymph node metastasis, and no distant metastasis), are being detected. Despite the relatively favorable prognosis of T1N0M0 PTC, the presence and burden of central lymph node metastasis (CLNM) remain critical factors that directly guide individualized treatment strategies and long-term follow-up plans for patients.

Similarly, the burden of CLNM exerts a pivotal impact on the individualized management of T1N0M0 PTC patients, as distinct metastasis burdens correspond to significantly different therapeutic approaches. Specifically, lymph node metastasis of any burden serves as an absolute contraindication to thermal ablation, a minimally invasive treatment option increasingly used for low-risk PTC; patients with low-burden CLNM (defined as ≤3 positive central lymph nodes with no extracapsular extension) are typically suitable for thyroid lobectomy combined with central lymph node dissection, which balances tumor control and preservation of thyroid function; in contrast, high-burden CLNM (defined as >3 positive central lymph nodes or presence of extracapsular extension) recommends total thyroidectomy with comprehensive central lymph node dissection, followed by radioactive iodine therapy when necessary to reduce the risk of recurrence. However, conventional preoperative imaging examinations, including conventional ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), have inherent limitations in diagnosing CLNM and evaluating its burden. Conventional ultrasound relies primarily on morphological features (e.g., lymph node size, shape, cortical thickness) which lack sufficient specificity, while CT and MRI are associated with radiation exposure (for CT) or high cost (for MRI) and still demonstrate low sensitivity and specificity for detecting small or micrometastatic lymph nodes in the central compartment, leading to frequent misdiagnosis or underdiagnosis.

This limitation poses a clinical dilemma: inaccurate preoperative assessment of CLNM burden may result in overtreatment (e.g., unnecessary total thyroidectomy in patients with no or low-burden metastasis, leading to lifelong thyroid hormone replacement therapy) or undertreatment (e.g., lobectomy in patients with high-burden metastasis, increasing the risk of local recurrence and the need for reoperation). Therefore, there is an urgent clinical need for a non-invasive, accurate, and cost-effective imaging method to preoperatively evaluate the burden of CLNM in T1N0M0 PTC patients.

Dynamic contrast-enhanced ultrasound (CEUS) has emerged as a promising imaging technique in the field of thyroid and lymph node diagnostics. By intravenously injecting a microbubble contrast agent, CEUS can dynamically visualize the microvascular perfusion of target tissues in real time, providing qualitative (e.g., enhancement pattern, homogeneity, presence of perfusion defects) and quantitative (e.g., time to peak, peak intensity, wash-in rate, wash-out rate) parameters that reflect the pathological microenvironment of lesions. Compared with conventional imaging modalities, CEUS offers several advantages, including non-radiation exposure, real-time imaging, high spatial and temporal resolution, and the ability to assess microcirculation, which may enable more accurate identification of metastatic lymph nodes and evaluation of their burden.

To address the aforementioned clinical gap, this multicenter retrospective cross-sectional study was designed to explore the value of CEUS in preoperatively predicting the burden of CLNM in T1N0M0 PTC patients. The study enrolled 600 consecutive patients with T1N0M0 PTC who were admitted to three tertiary hospitals (the lead center and two collaborating centers) from June 2018 to June 2025 and confirmed by postoperative pathology. All patients met strict inclusion criteria: (1) histopathologically confirmed PTC after surgery; (2) preoperative tumor staging consistent with T1N0M0 based on clinical examination and conventional imaging; (3) no history of thyroid surgery, radioactive iodine therapy, or other malignant tumors; (4) availability of complete preoperative CEUS data of the thyroid and central compartment lymph nodes; and (5) no contraindications to contrast agent injection. Patients with incomplete clinical, imaging, or pathological data were excluded from the study.

Two senior ultrasound physicians with more than 10 years of experience in thyroid and lymph node imaging, who were completely blinded to the postoperative pathological results (including the presence and burden of CLNM), independently analyzed the stored CEUS images. They extracted a comprehensive set of qualitative and quantitative CEUS features. Qualitative features included: (1) enhancement pattern of the thyroid lesion (homogeneous vs. heterogeneous, hyperenhancement vs. hypoenhancement vs. isenhancement compared with surrounding normal thyroid tissue, presence of peripheral rim enhancement); (2) enhancement characteristics of suspicious lymph nodes (homogeneous vs. heterogeneous enhancement, presence of perfusion defects, cortical enhancement, medullary hilum disappearance); and (3) time sequence of enhancement (whether the lesion/lymph node enhances earlier or later than normal tissue). Quantitative features were measured using dedicated offline analysis software, including time to peak (TTP), peak intensity (PI), wash-in slope (WIS), wash-out rate (WOR), and area under the time-intensity curve (AUC-TIC) for both the thyroid lesion and suspicious lymph nodes.

Taking postoperative pathological results as the gold standard (the gold standard for CLNM diagnosis and burden assessment), patients were divided into three groups: (1) non-metastasis group: no positive central lymph nodes confirmed by pathology; (2) low-burden metastasis group: ≤3 positive central lymph nodes with no extracapsular extension; (3) high-burden metastasis group: >3 positive central lymph nodes or presence of extracapsular extension (extracapsular extension was defined as the infiltration of metastatic lymph node tissue beyond the lymph node capsule into adjacent soft tissues). Pathological examination was performed by two senior pathologists who were blinded to the CEUS results, and any discrepancies were resolved through consensus discussion.

Statistical analysis was performed using SPSS 26.0 and R 4.2.0 software. First, inter-observer agreement for qualitative and quantitative CEUS features was evaluated using the kappa coefficient (for qualitative features) and intraclass correlation coefficient (ICC) (for quantitative features), with kappa/ICC >0.75 indicating excellent agreement. Features with excellent inter-observer agreement were included in subsequent analyses. Then, univariate Logistic regression analysis was used to screen potential predictors of CLNM burden (i.e., comparing non-metastasis vs. metastasis, and low-burden vs. high-burden metastasis). Variables with a P value \<0.1 in univariate analysis were included in multivariate Logistic regression analysis to identify independent predictors of CLNM burden. Based on the independent predictors, a combined predictive model was constructed, and the regression coefficient of each predictor was used to assign a weight to generate a risk score for CLNM burden.

To evaluate the diagnostic efficacy of the combined model, receiver operating characteristic (ROC) curves were drawn, and the area under the curve (AUC) was calculated as the primary outcome measure. The optimal cut-off value of the risk score was determined using the Youden index (sensitivity + specificity - 1). Secondary outcome measures included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy, which were calculated based on the optimal cut-off value. Additionally, decision curve analysis (DCA) was performed to evaluate the clinical practicality of the model by quantifying the net benefit of using the model to guide clinical decision-making compared with the "treat all" or "treat none" strategies across different threshold probabilities.

This study is expected to achieve several key objectives: first, to identify the most valuable qualitative and quantitative CEUS features for predicting the burden of CLNM in T1N0M0 PTC; second, to construct a reliable combined predictive model based on these CEUS features that can accurately distinguish between non-metastasis, low-burden metastasis, and high-burden metastasis preoperatively; third, to validate the diagnostic efficacy and clinical applicability of the model through ROC and DCA analyses. Ultimately, this project aims to provide a non-invasive, accurate, and practical tool for preoperative assessment of CLNM burden in T1N0M0 PTC patients, thereby guiding clinicians to formulate more precise and individualized treatment plans, reducing the risk of overtreatment or undertreatment, improving patient prognosis, and optimizing the use of medical resources.

03

Conditions studied

  • Thyroid Papillary Carcinoma
  • Contrast Enhanced Ultrasound

Keywords

  • thyroid papillary carcinoma
  • contrast enhanced ultrasound
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with T1N0M0 papillary thyroid carcinoma (PTC) who underwent initial surgical treatment and had preoperative evaluation confirmed as T1N0M0 at the medical centers participating in this study between June 2018 and June 2025.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with preoperative assessment of T1N0M0 papillary thyroid carcinoma who underwent initial surgical treatment at the medical centers participating in this study between June 2018 and June 2025.
  2. Definitive diagnosis of papillary thyroid carcinoma confirmed by postoperative histopathological examination.
  3. Preoperative conventional ultrasound and contrast-enhanced ultrasound (CEUS) examination of the thyroid and/or suspicious central lymph nodes were performed, with complete imaging data of acceptable quality for analysis.
  4. Surgical procedures included thyroidectomy (lobectomy or total thyroidectomy) combined with central lymph node dissection (prophylactic or therapeutic) to provide a definitive pathological gold standard for lymph nodes.
  5. Complete clinical pathological data and imaging data were retrievable from the Hospital Information System (HIS).

Exclusion criteria

Exclusion Criteria

  1. Preoperative receipt of any anti-tumor treatment targeting the thyroid (e.g., radiotherapy, chemotherapy, targeted therapy, or ablation therapy).
  2. Complication with other types of thyroid malignant tumors (e.g., medullary carcinoma, undifferentiated carcinoma, etc.).
  3. History of neck surgery or radiotherapy that may affect the structure of cervical lymph nodes.
  4. Complication with other systemic diseases that may affect CEUS perfusion characteristics or imaging evaluation (e.g., severe heart failure, liver cirrhosis, etc.).
  5. Allergy to components of the ultrasound contrast agent.
  6. Missing key clinical or imaging data, making complete analysis impossible.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • High Metastasis Burden Group

    ≥5 involved lymph nodes or the maximum diameter of any involved lymph node ≥2 mm

  • Low Metastasis Burden Group

    \<5 involved lymph nodes and the maximum diameter of all involved lymph nodes \<2 mm.

06

What researchers measure

Primary outcomes

  1. Invasiveness

    The burden of central lymph node metastasis. According to NCCN guidelines, The burden of central lymph node metastas is categorized as "high" (≥5 involved nodes or any metastatic focus ≥2 mm), "low" (\<5 involved nodes and all metastatic foci \<2 mm), and "none" (no central lymph node metastasis).

    Time frame: 2018-2025

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, Moons KGM, Collins G, van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020 Mar 18;368:m441. doi: 10.1136/bmj.m441. No abstract available. PubMed 32188600 ↗
  • Riley RD, Collins GS, Ensor J, Archer L, Booth S, Mozumder SI, Rutherford MJ, van Smeden M, Lambert PC, Snell KIE. Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome. Stat Med. 2022 Mar 30;41(7):1280-1295. doi: 10.1002/sim.9275. Epub 2021 Dec 16. PubMed 34915593 ↗
  • Luo ZY, Hong YR, Yan CX, Wang Y, Ye Q, Huang P. Utility of quantitative contrast-enhanced ultrasound for the prediction of lymph node metastasis in patients with papillary thyroid carcinoma. Clin Hemorheol Microcirc. 2022;80(1):37-48. doi: 10.3233/CH-200909. PubMed 33252064 ↗
  • Yu Y, Shi LL, Zhang HW, Wang Q. Performance of contrast-enhanced ultrasound for lymph node metastasis in papillary thyroid carcinoma: a meta-analysis. Endocr Connect. 2023 Jan 19;12(2):e220341. doi: 10.1530/EC-22-0341. Print 2023 Feb 1. PubMed 36524799 ↗
  • Li QL, Ma T, Wang ZJ, Huang L, Liu W, Chen M, Sang T, Ren XG, Tong J, Cao CL, Dong J, Li J. The value of contrast-enhanced ultrasound for the diagnosis of metastatic cervical lymph nodes of papillary thyroid carcinoma: A systematic review and meta-analysis. J Clin Ultrasound. 2022 Jan;50(1):60-69. doi: 10.1002/jcu.23073. Epub 2021 Oct 8. PubMed 34625988 ↗
  • Yang Z, Wang X, Tao T, Zou J, Qiu Z, Wang L, Du H, Chen N, Yin X. Diagnostic value of contrast-enhanced ultrasonography in the preoperative evaluation of lymph node metastasis in papillary thyroid carcinoma: a single-center retrospective study. BMC Surg. 2023 Oct 24;23(1):325. doi: 10.1186/s12893-023-02199-w. PubMed 37875825 ↗
  • Chen L, Chen L, Liang Z, Shao Y, Sun X, Liu J. Value of Contrast-Enhanced Ultrasound in the Preoperative Evaluation of Papillary Thyroid Carcinoma Invasiveness. Front Oncol. 2022 Jan 14;11:795302. doi: 10.3389/fonc.2021.795302. eCollection 2021. PubMed 35096595 ↗
  • Hong YR, Luo ZY, Mo GQ, Wang P, Ye Q, Huang PT. Role of Contrast-Enhanced Ultrasound in the Pre-operative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma. Ultrasound Med Biol. 2017 Nov;43(11):2567-2575. doi: 10.1016/j.ultrasmedbio.2017.07.010. Epub 2017 Aug 12. PubMed 28807450 ↗
  • Yang J, Zhang F, Qiao Y. Diagnostic accuracy of ultrasound, CT and their combination in detecting cervical lymph node metastasis in patients with papillary thyroid cancer: a systematic review and meta-analysis. BMJ Open. 2022 Jul 4;12(7):e051568. doi: 10.1136/bmjopen-2021-051568. PubMed 35788082 ↗
  • Zhao F, Wang P, Yu C, Song X, Wang H, Fang J, Zhu C, Li Y. A LASSO-based model to predict central lymph node metastasis in preoperative patients with cN0 papillary thyroid cancer. Front Oncol. 2023 Jan 25;13:1034047. doi: 10.3389/fonc.2023.1034047. eCollection 2023. PubMed 36761950 ↗
  • Zheng WH, Li C, Sun RH, Shui CY, Wang X, He TQ, Cai YC, Ning YD, Jiang J, Qin G, Zhou YQ, Liu W. [Advances in the research of central lymph node dissection for cN0 thyroid papillary carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Aug 7;55(8):799-803. doi: 10.3760/cma.j.cn115330-20200411-00289. Chinese. PubMed 32791784 ↗

Individual participant data

Plan to share: Yes — Preoperative dual-modality ultrasound files/reports (conventional/CEUS features of lesions/central lymph nodes); Clinical baseline data (age, gender, pathology subtype, TNM stage, thyroid function); Postoperative pathology data (metastatic central lymph node count, focus diameter). All data are anonymized (no personal info) to protect privacy. Eligible researchers (with ethics approval for thyroid cancer studies) may apply via the study's encrypted platform 12 months post-study completion. IPD is for non-commercial academic use only.

Supporting information: Study protocol

Time frame: 2025-2026

Access criteria: Eligible academic researchers (with ethics committee approval for thyroid cancer imaging-related studies) may access the de-identified IPD (including dual-modality ultrasound data, clinical baseline records, and postoperative pathology results of thyroid carcinoma patients). To request access, researchers need to submit a formal application to the study leading team (via email) detailing their research purpose; after review and approval, they will receive access credentials for the study's encrypted secure data-sharing platform.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 22, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357571
Responsible party
Jingliang Ruan (Associate Chief Physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) — Principal investigator
First posted
Jan 22, 2026
Start date
Dec 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Jingliang Ruan, Doctoral Degree
Contact
ruanjl3@mail.sysu.edu.cn
+86-13694202230
Xinmin Xiao, Master's Degree
Contact
1124507651@qq.com
+86-18420058253
Jingliang Ruan, Doctoral Degree
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion